NCT02276365已完成1 期
Relative Bioavailability of Both BI 10773 50 mg and Pioglitazone 45 mg After Co-administration Compared to BI 10773 and Pioglitazone Alone in Healthy Male Volunteers (an Open-label, Randomised, Crossover, Clinical Phase I Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 20
- 主要终点
- Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
研究概览
简要总结
The objective of the study was to investigate whether there is a drug-drug interaction between BI 10773 and pioglitazone when co-administered as multiple oral doses. Therefore, the relative bioavailabilities of BI 10773 and pioglitazone were determined when both drugs were given in combination compared with BI 10773 and pioglitazone given alone.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy males according to the following criteria:
- •Based upon a complete medical history, including the physical examination, vital signs (Blood Pressure (BP), Pulse Rate (PR)), 12-lead ECG (electrocardiogram), clinical laboratory tests
- •Age 18 to 50 years (incl.)
- •BMI 18.5 to 29.9 kg/m2 (incl.)
- •Signed and dated written informed consent prior to admission to the study in accordance with GCP (Good Clinical Practice) and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to drug or its excipients)
- •Intake of drugs with a long half-life (more than 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration or during the trial
- •Smoker (more than 10 cigarettes or more than 3 cigars or more than 3 pipes/day)
- •Inability to refrain from smoking on trial days
- •Alcohol abuse (more than 30 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration or during the trial)
- •Excessive physical activities (within one week prior to administration or during the trial)
- •ALT (Alanine transaminase) outside the normal range or any other laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •Galactose or lactose intolerance, galactose or glucose malabsorption
研究组 & 干预措施
Sequence ABC
Experimental
- Treatment A: 50 mg BI 10773 once daily from day 1 to 5
- Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
- Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out
干预措施: BI 10773 (Drug)
Sequence ABC
Experimental
- Treatment A: 50 mg BI 10773 once daily from day 1 to 5
- Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
- Treatment C: 45 mg pioglitazone once daily from day 1 to 7 after 7 days wash-out
干预措施: Pioglitazone (Drug)
Sequence CAB
Experimental
- Treatment C: 45 mg pioglitazone once daily from day 1 to 7
- Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out
- Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
干预措施: BI 10773 (Drug)
Sequence CAB
Experimental
- Treatment C: 45 mg pioglitazone once daily from day 1 to 7
- Treatment A: 50 mg BI 10773 once daily from day 1 to 5 after 7 days wash-out
- Treatment B: 50 mg BI 10773 and 45 mg pioglitazone once daily from day 1 to 7
干预措施: Pioglitazone (Drug)
结局指标
主要结局
Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: up to 10 days
AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
时间窗: up to 10 days
次要结局
- Changes from baseline in vital signs (Blood pressure, pulse rate)(Baseline and up to 10 days after last study drug administration)
- Changes from baseline in 12-lead ECG (electrocardiogram)(Baseline and up to 10 days after last study drug administration)
- C24,N (concentration of analyte in plasma at 24 hours post-drug administration after administration of the Nth dose)(up to 10 days)
- λz,ss (terminal half-life of the analyte in plasma)(up to 10 days)
- t½,ss (terminal half-life of the analyte in plasma at steady state)(up to 10 days)
- tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)(up to 10 days)
- Changes in clinical laboratory tests(Baseline and up to 10 days after last study drug administration)
- Incidence of adverse events(up to 35 days)
- MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)(up to 10 days)
- CLR,ss (renal clearance of the analyte at steady state)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- Assessment of tolerability by investigator on a 4-point scale(Within 3-10 days after last study drug administration)
- UGE0-24 (Urinary glucose excretion of the analyte in urine over the time interval from time zero to 24 h)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- CL/F,ss (apparent clearance of the analyte in the plasma after extravascular administration at steady state)(up to 10 days)
- Aet1-t2,ss (amount of analyte eliminated in urine at steady state over a uniform dosing interval τ)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- fet1-t2,ss (fraction of analyte excreted unchanged in urine at steady state over a uniform dosing interval τ)(1 hour pre-dose, 0-2, 2-4, 4-8, 8-12, 12-24 hours after last dosing)
- Abnormal findings in physical examination(Baseline and up to 10 days after last study drug administration)
- Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following extravascular administration)(up to 10 days)
研究者
相似试验
已完成
1 期
Relative Bioavailability of BI 10773 and Glimepiride in Healthy Male VolunteersHealthyNCT02172261Boehringer Ingelheim16
已完成
1 期
Bioavailability of BI 10773 and Sitagliptin in Healthy Male VolunteersHealthyNCT02172196Boehringer Ingelheim16
已完成
1 期
Drug-drug Interaction of Empagliflozin (BI 10773) and SimvastatinHealthyNCT01304329Boehringer Ingelheim18
已完成
1 期
Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy VolunteersHealthyNCT01111331Boehringer Ingelheim18
已完成
1 期
Relative Bioavailability BI 10773 and Metformin in Healthy Male VolunteersHealthyNCT02172248Boehringer Ingelheim16